Evaluation of HER-2/neu (erbB-2) status in breast cancer: From bench to bedside

Modern Pathology

Volumn 12, Issue 8, 1999, Pages 827-834

  Hanna, Wedad ^a,b   Kahn, Harriette J ^b   Trudeau, Maureen ^c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; HER 2 neu; Methodology

Indexed keywords

MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METHODOLOGY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0032875086     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Hayes DF, Bast RC, Desch CE, Fritche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
2. Gusterson BA. The change in the role of the pathologist in the prediction of tumor behaviour and response to treatment. In: Dickson RB, Lippman HE, editors. Drugs and hormonal resistance in breast cancer. New York: Ellis Harwood; 1995. p. 39-53.
3. Hanna W, Kahn HJ, Chapman JA, Fish EB, Lickley L, McCready D. Pathological characteristics of breast cancer that predict for local recurrence after lumpectomy alone. Breast J 1998;5:105-11.
4. Chu KC, Tarone RE, Kessler LG, Ries LA, Hankey BF, Miller BA, et al. Recent trends in US breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 1996;88:1571-9.
5. Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981;290:261-4.
6. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185-HER2 causes transformation and tumorigenesis of NIH3T3 cells. Proc Natl Acad Sci U S A 1987;84:7159-63.
7. King CR, Kraus MH, Aaronson SA. Amplification of a novel V-erbB-related gene in a human mammary carcinoma. Science 1985;229:974-6.
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ulich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 1987;235:177-82.
9. Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989;4:362-6.
10. Schechter Al, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumor antigen. Nature 1984; 312:513-6.
11. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319:226-30.
12. Zahar T, Yarden Y. The erbB-2/Her-2 oncogenic receptor for adenocarcinomas from orphanhood to multiple strand ligand. Biochem Biophys Acta 1998;1377:M25-M37.
13. Ali IU, Campbell G, Lidereau R, Callahan R. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. Oncogene Res 1988;3:139-46.
14. Berger MS, Locker GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988;48:1238-43.
15. Pauletti G, Godolphin W, Press M, Slamon D. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
16. Rajkumar T, Gullick WJ. The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 1994;29:3-9.
17. De Potter CR, Schelfhout AM. The neu protein and breast cancer. Virchows Arch 1995;426:107-15.
18. Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, et al. Prognostic significance of c-erbB-2 expression in node-negative breast cancer. Br J Cancer 1993;67: 625-9.
19. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50: 4332-7.
20. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991;51: 944-8.
21. Lovekin C, Ellis IO, Locker A, Robertson JFR, Bell J, Nicholson R, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63:439-43.
22. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BMJ, et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 1991;51:3296-303.
23. Noguchi M, Koyasaki N, Ohta N, Kitagawa H, Erashi M, Thomas M, et al. c-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 1992;69:2953-60.
24. O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA. The relationship between c-erbB-2 expression, S-phase fraction, and prognosis in breast cancer. Br J Cancer 1991;63:444-6.
25. Paterson MC, Dietrich KD, Kanyluk J, Paterson AHG, Lees AE, Jamil N, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991;54:556-67.
26. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. Immunohistochemical detection of HER-2/neu in patients with axillary lymph node-negative breast carcinoma. Cancer 1995;75:1320-6.
27. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 20-year follow-up. J Clin Oncol 1992;10:1044-8.
28. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605.
29. Albanell J, Bellmunt J, Molina R, Garcia M, Caragol I, Bermejo B, et al. Node-negative breast cancers with p53(-)/ HER2-neu(-) status may identify women with very good prognosis. Anticancer Res 1996;16:1027-32.
30. Dykins R, Corbett IP, Henry JA, Wright C, Yuan J, Hennessy C, et al. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 1991;163:105-10.
31. Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C, Sismonidi P. Prognostic and predictive relevance of c-erbB-2 and ras expression in node-positive and negative-breast cancer. Anticancer Res 1994;14:1441-50.
32. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, SeveSoderborgh J, AnbazhaganR, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10: 1049-56.
33. Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, et al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early-stage breast cancer. Ann Surg 1994;219:332-41.
34. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, et al. HER-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-70.
35. Quenel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, et al. The prognostic value of c-erbB-2 in primary breast carcinomas: a study of 942 cases. Breast Cancer Res Treat 1995;35:283-91.
36. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991;49:44-9.
37. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlar V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993;11: 1936-42.
38. Winstanley J, Cooke T, Murray GD, Platt-Higgins A, George WD, Holt S, et al. The long-term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991;63:447-50.
39. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-12.
40. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsy S, et al. neu/erbB-2 amplification identifies a poor prognosis group of women with node-negative breast cancer. J Clin Oncol 1998;16:1340-9.
41. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis, and poor long-term survival in breast cancer. Int J Cancer 1991;49:650-5.
42. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. erbB-2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991;6:137-43.
43. Anbazhagan R, Gelber RD, Bettelheim R, Goldhirsch A, Gusterson BA. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node-positive breast cancer. Ann Oncol 1991;2:47-53.
44. Borresen AL, Ottestad L, Gaustad A, Andersen TI, Heikkila R, Jahnsen T, et al. Amplification and protein overexpression of the neu/HER-2/c-erbB-2 proto-oncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history, and prognosis. Br J Cancer 1990; 62:585-90.
45. Hartmann LC, Ingle JN, Wold LE, Farr GH, Grill JP, Su JQ, et al. Prognostic value of c-erbB-2 overexpression in axillary lymph node-positive breast cancer: results from a randomized adjuvant treatment protocol. Cancer 1994;74:2956-63.
46. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
47. Schonborn I, Zschiesche W, Spitzer E, Minguillon C, Mohner M, Ebeling K, et al. c-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk. Breast Cancer Res Treat 1994;29:287-95.
48. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359-65.
49. Clark G. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erb-2 status? J Natl Cancer Inst 1998;90:1320-21.
50. Stal O, Sullivan S, Wingreen S, Skoog L, Rutqvist LE, Carstensen JM, et al. c-erb2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995;31:2185-90.
51. Thor AD, Berry AD, Budman DR, Muss HB, Kute T, Henderson IC, et al. ErbB2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90:1346-60.
52. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70.
53. Ravdin PM, Green S, Albain KS, Boucher V, Ingle J, Pritchard K, et al. Initial report of the SWOG biological correlation study of c-erb2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with tamoxifen (T) alone [abstract]. Proc ASCO 1998;17:97a.
54. Baselga J, Seidman AD, Rosen PP, Norton L. HER-2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 1997;11(3 Suppl 2):43-8.
55. Carlomagna C, Perrone F, Gallo C, de Laurentis M, Lauria R, Morabito A, et al. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14: 2702-8.
56. Newby JC, Johnston SRD, Smith IE, Dowsett M. Expression of epidermal growth factor receptor and c-erbB-2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997;3:1643-51.
57. Bianco AR, de Laurentis M, Carlomagna C, Lauria R, Petrella G, Panico L, et al. 20-year update of the Naples Gun trial of adjuvant breast cancer therapy: evidence of interaction between c-erbB-2 expression and tamoxifen efficacy [abstract]. Proc Am Soc Clin Oncol 1998;17:97a.
58. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 1998;4:7-12.
59. Pietras RJ, Poen JC, Gallardo P, Wonguipat N, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999;59:1347-55.
60. Haffty BG, Brown F, Carter D, Flynn S. Evaluation of HER-2/ neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study. Int J Radiat Oncol Biol Phys 1996;35:751-7.
61. Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Elliott C, et al. c-erbB-2 expression in benign and malignant breast disease. Br J Cancer 1998;589:453-7.
62. Hanna W, Kahn HJ, Andrulis I, Pawson T. Distribution and pattern of staining of neu oncogene product in benign and malignant breast diseases. Mod Pathol 1990;3:455-61.
63. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER-2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16: 2659-71.
64. Slamon D, Leyland-Jones B, Shak S, Paton V, et al. Addition of Herceptin (humanized anti-HER-2 antibody) to first-line chemotherapy for HER-2-overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial [abstract]. Proc ASCO 1998;17:98a.
65. McNeil C. Herceptin raises its sights beyond advanced breast cancer. J Natl Cancer Inst 1998;90:882-3.
66. Reid MC, Lachs MS, Feinstein AR. Use of methodological standards in diagnostic test research. JAMA 1995;274:645-51.
67. Heid CA, Stevens J, Livak K, Williams PM. Real-time quantitative PCR. Genome Res 1996;6:986-94.
68. Slamon DJ, Press MF, Godolphin W, Jones LA, Holt JA, Stuart SG, et al. Studies of the HER-2/neu proto-oncogene in human breast cancer. Cancer Cells 1989;7:371-82.
69. Battifora H, Gaffey M, Esteban J, Mehta P, Bailey A, Fancett C, et al. Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective follow-up study of 245 stage I and II cases. Mod Pathol 1991;4:466-74.
70. Press MF, Hung G, Godolphin GW, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7.
71. Kay WE, Walsh CJ, Cassidy M, Curran B, Leader M. c-erbB-2 immunostaining: problem with interpretation. J Clin Pathol 1994;47:816-22.
72. Keshgegian AA, Cnaan A. erbB-2 oncoprotein expression in breast carcinoma: poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody. Am J Clin Pathol 1997;108:456-63.
73. Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C, et al. Amplification and overexpression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991;63:601-8.
74. Kay WE, Mulcahy H, Walsh CB, Leader M, O'Donoghue D. Cytoplasmic c-erbB-2 protein expression correlates with survival in Duke's B colorectal carcinoma. Histopathology 1994;25:455-61.
75. Roychowdhury DF, Tseng A Jr, Fu KK, Weinberg V, Weidner N. New prognostic factors in nasopharyngeal carcinoma: tumor angiogenesis and c-erbB-2 expression. Cancer 1996; 77:1419-26.
76. Akslen LA, Varhaug JE. Oncoprotein and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor-related protein, p21 ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 1995;76:1643-54.